CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 227 enrolled
Drug / intervention
Sacituzumab Govitecan-hziydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03964727
NCT03964727Phase 2Active
CompareCT.gov

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Gilead Sciences·interventional·Posted May 28, 2019·Updated Apr 28, 2026

In Brief

A Phase 2 clinical trial evaluating Sacituzumab Govitecan-hziy for Metastatic Solid Tumor. Active but no longer recruiting, targeting 227 participants across 65 sites in 8 countries.

Detailed Summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Solid Tumor
CountriesAustralia, Belgium, Canada, France, Hong Kong, Spain, Taiwan, United States
Collaborators--

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedMay 28, 2019
Enrollment StartOct 15, 2019
Primary CompletionJan 15, 2025
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 7.1 years ago

Interventions

Sacituzumab Govitecan-hziydrug

Administered intravenously